The two products that the two companies will be jointly selling are Akab and Tubero, a combination drug of Kanab, an existing high blood pressure treatment, and a treatment for hyperlipidemia, among Boryeong Pharmaceutical’s representative blockbuster new drug Kanab family.
Tubero was launched in 2016 as a product that improves the patient’s medication convenience by combining fimasartan, a component of the new high blood pressure drug Kanab, and rosuvastatin, a treatment component for hyperlipidemia. Akab is a new product that was launched this year as a combination of Kanab’s ingredient fimasartan and atorvastatin, which is used as a treatment for hyperlipidemia. Since many hypertensive patients have hyperlipidemia, the proportion of combination drugs in the hypertension treatment market is constantly increasing.
With this contract, the distribution, sales and marketing of Tubero to all domestic hospitals and clinics will be handled by Daewon Pharmaceutical, while the distribution of Akab will be conducted by Daewon Pharmaceutical, and sales and marketing will be jointly conducted by the two companies.
Ahn Jae-hyun, CEO of Boryeong Pharmaceutical said, “The Kanab family is recognized for its marketability at home and abroad through its excellent clinical value as a successful model for domestic new drugs. Through this cooperation, it goes beyond becoming another successful model for cooperation between domestic companies. “We look forward to helping more patients improve their quality of life.”
Daewon Pharmaceutical Vice Chairman Seung-Yeol Baek said, “We will contribute to expanding the market share of the Kanab brand based on Daewon Pharmaceutical’s differentiated marketing capabilities and sales know-how so that more hypertension and hyperlipidemia patients can benefit from the treatment benefits of the innovative new drug Kanab Family. Will,” he replied.
Meanwhile, according to the drug research institute UBIST, the domestic hypertension/hyperlipidemia combination market is estimated to be about KRW 114.3 billion by the third quarter of this year. The Kanab Family recorded a cumulative prescription amount of 94.3 billion won until November, and this year’s breakthrough of 100 billion won is strong.
.jpg?resize=520%2C346 "최태홍 대원제약 사장과 안재현 보령제약 대표가 카나브 패밀리 2종의 공동 판매 계약을 체결하고 있다. 사진/대원제약")
Tae-Hong Choi, CEO of Daewon Pharmaceutical and Jae-Hyun Ahn, CEO of Boryeong Pharmaceutical, are signing a joint sales contract for two types of Kanab Family. Photo/Daewon Pharmaceutical
Reporter Kijong Jung [email protected]
Ⓒ Delicious news tomatoes, reprinted without permission-Redistribution prohibited